Skip to main content

Cogenics Partners with SinoGenoMax in China

NEW YORK (GenomeWeb News) — Beijing-based genomics research services company SinoGenoMax will offer Cogenics’ genotyping services in China, Cogenics' parent company, Clinical Data, said today.

"Our partnership with SinoGenoMax provides us with an established presence in China and an experienced international service partner who operates with similar platforms and high quality standards," Cogenics Global Manager Michael Lutz said in a statement. "The extensive pharmaceutical and biotechnology infrastructure and large number of clinical trials conducted in China make this an increasingly important market for clinical genotyping services."

SinoGenoMax CEO Danny Ching said the partnership also "represents a significant opportunity for SinoGenoMax to widen its international spectrum."

Cogenics has facilities in North Carolina, Texas, the United Kingdom, France, and Germany.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.